Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

CompletedOBSERVATIONAL

Enrollment

779

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions

Breast Cancer

Interventions

DRUG

Palbociclib

Palbociclib with an aromatase inhibitor therapy

DRUG

Aromatase Inhibitor

Aromatase Inhibitor Therapy

Trial Locations (1)

Pfizer New York, New York